{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:07:52Z","timestamp":1791259672374,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1038\/nrclinonc.2011.212","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T11:45:17Z","timestamp":1326195917000},"page":"72-74","source":"Crossref","is-referenced-by-count":12,"title":["New therapeutic targets and treatment strategies"],"prefix":"10.1038","volume":"9","author":[{"given":"Paula","family":"Cramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"BFnrclinonc2011212_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ccr.2011.06.029","volume":"20","author":"Y Kikushige","year":"2011","unstructured":"Kikushige, Y.  et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246\u2013259 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2011212_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente, X. S.  et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101\u2013105 (2011).","journal-title":"Nature"},{"key":"BFnrclinonc2011212_CR3","doi-asserted-by":"publisher","unstructured":"Wang, L.  et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. \n                    http:\/\/dx.doi.org\/10.1056\/NEJMoa1109016\n                    \n                  .","DOI":"10.1056\/NEJMoa1109016"},{"key":"BFnrclinonc2011212_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G.  et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","journal-title":"Lancet"},{"key":"BFnrclinonc2011212_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","volume":"28","author":"E Bachy","year":"2010","unstructured":"Bachy, E.  et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 28, 822\u2013829 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2011212_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert, A.  et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma N. Engl. J. Med. 363, 640\u2013652 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2011212_CR7","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"P Borchmann","year":"2011","unstructured":"Borchmann, P.  et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J. Clin. Oncol. 29, 4234\u20134242 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2011212_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani, S.  et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203\u2013212 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2011212_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","volume":"29","author":"J Ruan","year":"2011","unstructured":"Ruan, J.  et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 690\u2013697 (2011).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.212","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:07:59Z","timestamp":1684469279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2011.212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,10]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["BFnrclinonc2011212"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2011.212","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,10]]}}}